139755-85-4

Basic information

• Product Name: Hydroxyhomosildenafil
• Synonyms: Hydroxyhomosildenafil;5-[2-Ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-1,6-dihydro-1-Methyl-3-propyl-7H-pyrazolo[4,3-d]pyriMidin-7-one;Lodenafil
• CAS NO: 139755-85-4
• Molecular Formula: C₂₃H₃₂N₆O₅S
• Molecular Weight: 504.60238
• Product Categories: Aromatics;Drug Analogues;Heterocycles;Sulfur & Selenium Compounds
• Mol File: 139755-85-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 183-185?C
• Boiling Point: 730.6oC at 760 mmHg
• Flash Point: 395.7oC
• Appearance: /
• Density: 1.42g/cm3
• Vapor Pressure: 2.08E-22mmHg at 25°C
• Refractive Index: 1.667
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 10.05±0.20(Predicted)
• CAS DataBase Reference: Hydroxyhomosildenafil(CAS DataBase Reference)
• NIST Chemistry Reference: Hydroxyhomosildenafil(139755-85-4)
• EPA Substance Registry System: Hydroxyhomosildenafil(139755-85-4)

Safety Data

• Hazardous Substances Data: 139755-85-4(Hazardous Substances Data)

Usage

Chemical Properties

Pale Yellow Solid

Uses

Different sources of media describe the Uses of 139755-85-4 differently. You can refer to the following data:
1. A Sildenafil (S435000) analog, enhances male sexual function.
2. A Sildenafil (S435000) analog, enhances male sexual function

InChI:InChI=1/C23H32N6O5S/c1-4-6-18-20-21(27(3)26-18)23(31)25-22(24-20)17-15-16(7-8-19(17)34-5-2)35(32,33)29-11-9-28(10-12-29)13-14-30/h7-8,15,30H,4-6,9-14H2,1-3H3,(H,24,25,31)

Upstream product

• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 1357931-55-5 4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzenesulfonic acid 
• 139756-21-1 5-(2-ethoxy)-phenyl-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidine-7-one 
• 613-69-4 2-ethoxylbenzaldehyde 
• 139756-22-2 5-(5-Chlorosulphonyl-2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 
• 139756-03-9 4-[(2-ethoxybenzoyl)amino]-1-methyl-3-propyl-1H-pyrazole-5-carboxamide 
• 139756-02-8 4-amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide 
• 42926-52-3 2-ethoxybenzoyl chloride 

Downstream Products

• 1007310-72-6 C₃₃H₅₀N₆O₆S 
• 1023327-69-6 5-{2-ethoxy-5-[(4-chlorobutyric acid ethyl ester)piperazin-1-ylsulfonyl]phenyl}-1-methyl-3-N-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 

Relevant articles and documents

Sulphonated graphene oxide catalyzed continuous flow synthesis of pyrazolo pyrimidinones, sildenafil and other PDE-5 inhibitors

Sulphonated graphene oxide was used for cascade condensation and cyclization reactions towards accessing substituted pyrazolo pyrimidinones. Further, sulphonation and amination reactions were integrated through continuous flow chemistry to access PDE-5 inhibitors. Herein, we report a simple continuous synthetic platform that reduce tedious manual operations and accelerate the synthesis of several potent inhibitors of phosphodiesterase type-5. The developed platform enabled us to perform one-flow multi-step, multi-operational process to synthesize the PDE-5 inhibitors such as sildenafil and its analogues in 32.3 min of the reaction time, with minimal human intervention and single solvent.

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction

This invention is directed to the use phosphodiesterase type 5 (PDE5) inhibitors in the treatment of selective serotonin reuptake inhibitor (SSRI) induced sexual dysfunction. Specifically, this invention is directed to a method for treating an animal to cure; prevent or ameliorate SSRI induced sexual dysfunction which comprises administering to the animal an effective amount of the inhibitor. The animal may be a male or a female human. The invention also includes the use of such inhibitors in the manufacture of a medicament to prevent; cure or ameliorate SSRI induced sexual dysfunction. Moreover, the invention includes a kit comprising a SSRI, such as sertraline, fluoxetine, paroxetine, and a PDE5 inhibitor, such as sildenafil citrate, for the treatment or prevention of serotonergic associated disorders such as depression, obsessive compulsive disorder or panic disorder, while reducing or preventing sexual dysfunction.

Pyrazolopyrimidinones for the treatment of impotence

The use of a compound of formula (I) wherein R1is H; C1-C3alkyl; C1-C3perfluoroalkyl; or C3-C5cycloalkyl; R2is H; optionally substituted C1-C6alkyl; C1-C3perfluoroalkyl; or C3-C6cycloalkyl; R3is optionally substituted C1-C6alkyl; C1-C6perfluoroalkyl; C3-C5cycloalkyl; C3-C6alkenyl; or C3-C6alkynyl; R4is optionally substituted C1-C4alkyl, C2-C4alkenyl, C2-C4alkanoyl, (hydroxy)C2-C4alkyl or (C2-C3alkoxy)C1-C2alkyl; CONR5R6; CO2R7; halo; NR5R6; NHSO2NR5R6; NHSO2R8; SO2NR9R10; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R5and R6are each independently H or C1-C4alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R11)-piperazinyl or imidazolyl group; R7is H or C1-C4 alkyl; R8is optionally substituted C1-C3alkyl; R9and R10together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R12)-piperazinyl group; R11is H; optionally substituted C1-C3alkyl; (hydroxy)C2-C3alkyl; or C1-C4alkanoyl; R12is H; optionally substituted C1-C6alkyl; CONR13R14; CSNR13R14; or C(NH)NR13R14; and R?13? and R14are each independently H; C1-C4alkyl; or substituted C2-C4alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.